Defining the mechanism of action of the nitrofuranyl piperazine HC2210 against Mycobacterium abscessus

Area of Science:

• Microbiology
• Drug Discovery
• Antimicrobial Resistance

Background:

• Mycobacterium abscessus (Mab) infections are difficult to treat due to intrinsic antibiotic resistance.
• Existing treatments for non-tuberculous mycobacterial (NTM) infections are limited.
• Nitrofuranyl piperazines have shown prior activity against Mycobacterium tuberculosis (Mtb).

Purpose of the Study:

• To evaluate the activity of HC2210 against Mycobacterium abscessus (Mab).
• To elucidate the mechanism of action of HC2210 in Mab.
• To assess the potential of HC2210 as a novel therapeutic agent for Mab infections.

Main Methods:

• In vitro susceptibility testing of HC2210 against Mab clinical isolates.
• Determination of synergistic activity with existing antibiotics (bedaquiline, clarithromycin, meropenem).
• Resistance mutation analysis and transcriptional profiling.

Main Results:

• HC2210 demonstrated potent activity against Mab, exceeding amikacin's efficacy by fivefold.
• The compound was effective against multidrug-resistant Mab strains.
• Synergy was observed with bedaquiline, clarithromycin, and meropenem.
• Resistance mechanisms involved cofactor F420 and glycerol kinase (glpK).
• HC2210 modulated oxidative stress and lipid metabolism gene expression distinct from Mtb.

Conclusions:

• HC2210 is a promising candidate for treating Mab infections.
• Its unique mechanism and synergistic potential warrant further development.
• The HC2210 series could offer a new therapeutic strategy against challenging NTM infections.